entity-batch: update 2 entities
- Applied 2 entity operations from queue - Files: domains/entertainment/ai-video-generation-crossed-episodic-production-threshold-2026-amazon-prime-deployment.md, domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md Pentagon-Agent: Epimetheus <968B2991-E2DF-4006-B962-F5B0A0CC8ACA>
This commit is contained in:
Teleo Agents
parent
f571cfb899
commit
78df209672
2 changed files with 25 additions and 0 deletions
|
|
@ -12,6 +12,20 @@ scope: structural
|
|||
sourcer: VP-Land / The Wrap / Hollywood Reporter
|
||||
supports: ["GenAI is simultaneously sustaining and disruptive depending on whether users pursue progressive syntheticization or progressive control", "non-ATL production costs will converge with the cost of compute as AI replaces labor across the production chain", "character-consistency-unlocks-ai-narrative-filmmaking-by-removing-technical-barrier-to-multi-shot-storytelling"]
|
||||
related: ["GenAI is simultaneously sustaining and disruptive depending on whether users pursue progressive syntheticization or progressive control", "non-ATL production costs will converge with the cost of compute as AI replaces labor across the production chain", "character-consistency-unlocks-ai-narrative-filmmaking-by-removing-technical-barrier-to-multi-shot-storytelling"]
|
||||
|
||||
### Auto-enrichment (near-duplicate conversion, similarity=1.00)
|
||||
*Source: PR #10377 — "ai video generation crossed episodic production threshold 2026 amazon prime deployment"*
|
||||
*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
|
||||
|
||||
related: ["GenAI is simultaneously sustaining and disruptive depending on whether users pursue progressive syntheticization or progressive control", "non-ATL production costs will converge with the cost of compute as AI replaces labor across the production chain", "character-consistency-unlocks-ai-narrative-filmmaking-by-removing-technical-barrier-to-multi-shot-storytelling", "ai-video-generation-crossed-episodic-production-threshold-2026-amazon-prime-deployment", "house-of-david", "ai-video-production-workflow-creates-editorial-abundance-through-generation-ratio-not-asset-scarcity", "the-wonder-project"]
|
||||
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** CineD, Kling 3.0 coverage, February 2026
|
||||
|
||||
Kling 3.0's multi-shot storyboarding (6 cuts per generation), Subject Binding for character consistency, and integrated voice binding that animates correct lips in sync provides specific technical mechanisms enabling episodic production. The 15-second generation length combined with multi-shot capability means complete dialogue scenes are now possible in single generation passes, removing the manual assembly barrier.
|
||||
|
||||
---
|
||||
|
||||
# AI video generation crossed from experimental to planned episodic production workflow at major streamer scale in 2026
|
||||
|
|
|
|||
|
|
@ -14,6 +14,17 @@ challenges: ["medical care explains only 10-20 percent of health outcomes becaus
|
|||
related: ["glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation", "medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm", "glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "hedonic-eating-dopamine-circuit-adapts-to-glp1-suppression-explaining-continuous-delivery-requirement", "behavioral-biological-health-dichotomy-false-for-reward-dysregulation-conditions", "glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population", "glp1-receptor-agonists-reduce-alcohol-use-disorder-risk-28-36-percent-across-5-26-million-patients", "glp1-anhedonia-tonic-receptor-occupancy-dose-dependent-reversible", "glp1-cns-efficacy-circuit-specific-reward-dopamine-success-neurodegeneration-failure", "glp1-cns-effects-circuit-specific-reward-not-neurodegenerative"]
|
||||
supports: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery", "GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration"]
|
||||
reweave_edges: ["The behavioral-biological health determinant dichotomy is false for obesity because what appears as behavioral overconsumption is dopamine reward dysregulation continuously activated by the food environment|supports|2026-04-24", "Hedonic eating is mediated by dopamine reward circuits that adapt to GLP-1 suppression explaining both why GLP-1s work and why they require continuous delivery|supports|2026-04-24", "GLP-1 receptor agonist CNS efficacy is circuit-specific producing large effects in reward/dopamine-mediated conditions while failing in amyloid/tau-driven neurodegeneration|supports|2026-05-08"]
|
||||
|
||||
### Auto-enrichment (near-duplicate conversion, similarity=1.00)
|
||||
*Source: PR #10391 — "glp1 receptor agonists address substance use disorders through mesolimbic dopamine modulation"*
|
||||
*Auto-converted by substantive fixer. Review: revert if this evidence doesn't belong here.*
|
||||
|
||||
## Extending Evidence
|
||||
|
||||
**Source:** Abegaz et al., Frontiers in Psychiatry 2026
|
||||
|
||||
Cross-substance effect consistency (OR range 0.25-0.32 across alcohol, opioid, nicotine, cocaine) supports shared mesolimbic dopamine mechanism rather than substance-specific pathways. The cocaine use disorder effect size (OR=0.25, 75% lower odds) is particularly notable—no behavioral intervention produces comparable CUD reduction, suggesting GLP-1 receptor agonists may represent the largest treatment effect for cocaine use disorder in the literature if causal relationship holds.
|
||||
|
||||
---
|
||||
|
||||
# GLP-1 receptor agonists may address multiple substance use disorders through shared mesolimbic dopamine circuit modulation with 33 clinical trials underway across alcohol opioid nicotine and cocaine use
|
||||
|
|
|
|||
Loading…
Reference in a new issue